Press Releases May 28, 2026 04:05 PM

CG Oncology to Present at Upcoming Investor Conferences in June

CG Oncology to Present at Major Healthcare Investor Conferences in June 2026

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
CGON

CG Oncology, Inc. announced that its Chairman, President & CEO, Arthur Kuan, will participate in presentations at the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference in early June 2026. The company focuses on developing innovative immunotherapies for bladder cancer and will webcast the sessions for investor access.

CG Oncology to Present at Upcoming Investor Conferences in June
CGON
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CG Oncology’s CEO will present at two significant healthcare investment conferences in June 2026.
  • The company specializes in late-stage clinical development of bladder cancer immunotherapies aiming to offer bladder-sparing treatments.
  • Live webcasts and archived presentations will be available to investors, enhancing transparency and engagement.

DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference this month. The details of the upcoming events are as follows:

Jefferies Global Healthcare Conference 
Date: Wednesday, June 3, 2026
Presentation Time: 10:30-11:00 AM ET
Location: New York, New York

Goldman Sachs 47th Annual Global Healthcare Conference
Date: Tuesday, June 9, 2026
Presentation Time: 2:40-3:15 PM ET
Location: Miami, Florida

Interested parties may access the live audio webcast for the conferences from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replays will be available shortly after the conclusion of the live presentations and archived for approximately 90 days.

About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.

Contacts

Media 
Sarah Connors
Vice President, Communications and Patient Advocacy, CG Oncology
sarah.connors@cgoncology.com

Investor Relations
Megan Knight
Vice President, Investor Relations, CG Oncology
megan.knight@cgoncology.com


Risks

  • The company's products are still in clinical development, so regulatory and clinical trial risks remain high.
  • Market competition in oncology immunotherapies could impact CG Oncology’s commercial success.
  • Investor interest can be influenced by conference presentations but may not translate into immediate financial gains.

More from Press Releases

onsemi Introduces Industry-First Elite Pairing Studio to Simplify Power Design Jun 8, 2026 Ingredion Announces Recommended All-Cash Acquisition of Tate & Lyle Jun 8, 2026 Rackspace Technology Establishes Regional Headquarters in Riyadh to Accelerate Cloud and AI Growth Jun 8, 2026 WISeKey, The Hashgraph Group and Hedera Launch QAIT Q-Day Security Assessment Platform on the SEALCOIN Quantum Marketplace Jun 8, 2026 Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology Jun 8, 2026